Published in Endocr Pract on October 01, 2008
Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance | NCT02621060
Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA (2012) 4.04
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ (2012) 2.04
Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care (2009) 1.43
Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management. Curr Diab Rep (2014) 1.22
The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring) (2013) 1.21
Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care (2011) 1.05
Therapeutic interventions to reduce the risk of progression from prediabetes to type 2 diabetes mellitus. Ther Clin Risk Manag (2014) 1.00
The multi-systemic nature of diabetes mellitus: Genotype or phenotype? N Am J Med Sci (2010) 0.99
Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract. Nutr Metab (Lond) (2010) 0.98
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. Expert Rev Cardiovasc Ther (2009) 0.90
Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther (2009) 0.88
A novel use of structural equation models to examine factors associated with prediabetes among adults aged 50 years and older: National Health and Nutrition Examination Survey 2001-2006. Diabetes Care (2013) 0.88
Cytokine profiling of young overweight and obese female African American adults with prediabetes. Cytokine (2013) 0.87
Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. Int J Clin Pract (2009) 0.86
Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes. J Diabetes Sci Technol (2015) 0.84
Incretin therapy--present and future. Rev Diabet Stud (2011) 0.84
Role of voglibose in the treatment of prediabetes in Indian population: a cross-speciality survey. J Clin Diagn Res (2013) 0.81
Effect of concomitant administration of trospium chloride extended release on the steady-state pharmacokinetics of metformin in healthy adults. Clin Drug Investig (2013) 0.81
Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad. Cardiol Res Pract (2011) 0.80
Prevalence of normoglycemic, prediabetic and diabetic A1c levels. World J Diabetes (2013) 0.79
Liver inflammation is a risk factor for prediabetes in at-risk latinos with and without hepatitis C infection. Liver Int (2014) 0.78
Risk of postprandial insulin resistance: the liver/vagus rapport. Rev Endocr Metab Disord (2014) 0.78
Social inequalities in prevalence of diagnosed and undiagnosed diabetes and impaired glucose regulation in participants in the Health Surveys for England series. BMJ Open (2016) 0.75
Measuring the sweet smell of success in diabetes management. Ann Transl Med (2014) 0.75
Short term follow-up of prediabetics undergoing elective percutaneous coronary intervention. J Saudi Heart Assoc (2013) 0.75
Do Behavioral Risk Factors for Prediabetes and Insulin Resistance Differ across the Socioeconomic Gradient? Results from a Community-Based Epidemiologic Survey. Int J Endocrinol (2015) 0.75
Oral glucose tolerance test-based calculation identifies different glucose intolerance phenotypes within the impaired fasting glucose range. J Diabetes Investig (2014) 0.75
Incidence of prediabetes and risk of developing cardiovascular disease in women with polycystic ovary syndrome. Bosn J Basic Med Sci (2016) 0.75
The profile of hypertension and dyslipidemia in prediabetic subjects; results of the Isfahan Diabetes Prevention program: A large population-based study. Adv Biomed Res (2015) 0.75
Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utility. Integr Blood Press Control (2009) 0.75
Adiponectin and pro-inflammatory cytokines are modulated in Vietnamese patients with type 2 diabetes mellitus. J Diabetes Investig (2016) 0.75
Consensus on the Prevention of Type 2 Diabetes in Chinese Adults. Chin Med J (Engl) (2017) 0.75
A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide. Vasc Health Risk Manag (2013) 0.75
Phosphate Additive Avoidance in Chronic Kidney Disease. Diabetes Spectr (2017) 0.75
Development and validation of prediabetes risk score for predicting prediabetes among Indonesian adults in primary care: Cross-sectional diagnostic study. Interv Med Appl Sci (2017) 0.75
Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome. J Nat Sci (2017) 0.75
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care (2003) 29.49
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care (2007) 8.43
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract (2007) 7.55
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract (2009) 7.06
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55
Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13
Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA (2010) 6.11
Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res (2004) 5.74
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet (2007) 5.74
The PedsQL in type 1 and type 2 diabetes: reliability and validity of the Pediatric Quality of Life Inventory Generic Core Scales and type 1 Diabetes Module. Diabetes Care (2003) 5.62
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med (2004) 5.45
American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care (2009) 5.41
Diabetes enhances vulnerability to particulate air pollution-associated impairment in vascular reactivity and endothelial function. Circulation (2005) 5.07
AACE comprehensive diabetes management algorithm 2013. Endocr Pract (2013) 4.88
B-type natriuretic peptide in cardiovascular disease. Lancet (2003) 4.80
Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract (2011) 4.69
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA (2012) 4.04
American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Endocr Pract (2009) 3.96
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Rapid microsatellite identification from Illumina paired-end genomic sequencing in two birds and a snake. PLoS One (2012) 3.71
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med (2010) 3.56
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care (2007) 3.56
Race and gender differences in C-reactive protein levels. J Am Coll Cardiol (2005) 3.51
American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract (2012) 3.29
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation (2003) 3.22
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes (2006) 3.14
Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care (2003) 3.08
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care (2004) 3.00
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care (2012) 2.89
Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2016) 2.87
Prevalence and determinants of troponin T elevation in the general population. Circulation (2006) 2.84
Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation (2003) 2.80
Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J (2005) 2.71
The epidemiology of fetal alcohol syndrome and partial FAS in a South African community. Drug Alcohol Depend (2006) 2.71
Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care (2004) 2.55